WEIGAO GROUP

Shandong Weigao Medical Polymer shares weakened on 31 July, retreating from the opening price of HKD 3.410 in the morning session to HKD 3.390 by late morning, then extending losses to close at HKD 3.360, marking a 1.47% net intraday decline. The selloff was primarily driven by Morgan Stanley's recent downgrade of the price target to HKD 4.50, which has heightened market concerns over earnings sustainability and profitability trajectory. Financial results have deteriorated noticeably, with Q4 2025 EPS falling 35.3% year-on-year to HKD 0.0722 and Q3 2025 EPS declining 38.96% year-on-year in comparison to the prior year periods, though the company did achieve revenue growth of 9.28% year-on-year in Q4. Despite management's active share repurchase program implemented in recent weeks to support the stock, investor sentiment has grown cautious as shares already trade below the Morgan Stanley target price, suggesting limited near-term upside.

Weigao rose 1.47% to HK$3.44 today, opening lower at HK$3.38 in morning session before rebounding to HK$3.44 by mid-morning and closing at session highs. Recent earnings have disappointed—Q4 EPS dropped 35.3% year-over-year and net profit fell 34.2%—sending the stock tumbling 53.5% from its 52-week high of HK$7.39. Morgan Stanley recently cut its target to HK$4.5 with Equalweight rating. Management's steady buybacks and parent company stake increase, combined with low valuations (P/E 8.69, dividend yield 5.11%), appear to be attracting value investors at depressed levels. Year-to-date the stock is down 31.9%, with profit recovery still requiring verification.

1066.HK rebounded 2% to HKD 3.36 today, though the rally masks continued fundamental deterioration. Recent earnings reveal severe weakness: Q4 2025 EPS plunged 35% to HKD 0.0722 and net profit fell 34%, with Q3 showing steeper declines of 39% in EPS and 38% in net profit despite revenue growth of 9%+ in Q4. The stock has crashed 54% from its 52-week high and declined 33% year-to-date, signaling deep market pessimism. Morgan Stanley recently cut its target price to HKD 4.5, confirming bearish sentiment, while earnings data in this context look particularly concerning. The company's board is reviewing interim results, a forthcoming report that could prove decisive for near-term direction. Despite low valuation metrics (PE 8.49, PB 0.57), the discount reflects fundamental distress rather than value opportunity.

Stock rose 0.92%, driven by morning strength that pushed it from 3.230 to intraday high of 3.320, though afternoon profit-taking limited gains. Q4 revenue of HKD 3.75 billion rose 9.28% YoY, but net profit of HKD 336 million fell 34.19% YoY; EPS declined 35.31% YoY, with earnings pressure offsetting sentiment gains. Trading near 52-week lows, the stock is down 34.85% year-to-date and off its 7.39 high by over 55%. Recent share buybacks at 3.44 reflect management confidence, while Morgan Stanley cut target price from 5.2 to 4.5, rating Equalweight; valuation appears low at PE 8.31x and PB 0.56x, though continued profit contraction deserves close monitoring.

Weigao slipped 0.9% to close at HKD 3.26, with Morgan Stanley's recent downgrade of its target price to HKD 4.5 (Equalweight rating) weighing on the stock. The company has continued share buybacks at HKD 3.44, signaling confidence in underlying value despite near-term headwinds. Recent earnings reveal significant margin pressure — EPS fell over 35% year-on-year in both Q3 and Q4 2025, while revenue growth slowed to single digits. Stock has declined 35.45% year-to-date from HKD 5.05 and trades 56% below its 52-week high of HKD 7.39, reflecting steep depreciation over the period. Current valuation metrics appear stretched — PE 8.23 and PB 0.55 suggest low pricing, though persistent earnings weakness may test support.